Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Knox

Showing results (751-760 of 829) with videos related to

Pageof 83
Sort By:
Cancer|May 23, 2013
Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteriaNils Kroeger, Wanling Xie, Jae-Lyn Lee, et al.
Oncology|August 25, 2010
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access programRonald M Bukowski, Walter M Stadler, David F McDermott, et al.
British Journal of Cancer|April 3, 2014
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDCJ J Ko, T K Choueiri, B I Rini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyDaniel Y C Heng, Wanling Xie, Meredith M Regan, et al.
European Urology|June 17, 2014
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database ConsortiumDaniel Y C Heng, J Connor Wells, Brian I Rini, et al.
Cancer Medicine|April 18, 2017
Characterizing the outcomes of metastatic papillary renal cell carcinomaJohn Connor Wells, Frede Donskov, Anna P Fraccon, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 26, 2015
Discovery of D1 Dopamine Receptor Positive Allosteric Modulators: Characterization of Pharmacology and Identification of Residues that Regulate Species SelectivityMartin A Lewis, Lisa Hunihan, John Watson, et al.
Scientific Reports|May 20, 2021
Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancersNhu-An Pham, Nikolina Radulovich, Emin Ibrahimov, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 21, 2023
Symptom screening with Targeted Early Palliative care (STEP) versus usual care for patients with advanced cancer: a mixed methods studyCamilla Zimmermann, Ashley Pope, Breffni Hannon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 17, 2022
Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer?Yifan Wang, Adeline Cuggia, Yen-I Chen, et al.
Pageof 83

Showing results (751-760 of 829) with videos related to

Sort By:
Pageof 83
Cancer|May 23, 2013
Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteriaNils Kroeger, Wanling Xie, Jae-Lyn Lee, et al.
Oncology|August 25, 2010
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access programRonald M Bukowski, Walter M Stadler, David F McDermott, et al.
British Journal of Cancer|April 3, 2014
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDCJ J Ko, T K Choueiri, B I Rini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyDaniel Y C Heng, Wanling Xie, Meredith M Regan, et al.
European Urology|June 17, 2014
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database ConsortiumDaniel Y C Heng, J Connor Wells, Brian I Rini, et al.
Cancer Medicine|April 18, 2017
Characterizing the outcomes of metastatic papillary renal cell carcinomaJohn Connor Wells, Frede Donskov, Anna P Fraccon, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 26, 2015
Discovery of D1 Dopamine Receptor Positive Allosteric Modulators: Characterization of Pharmacology and Identification of Residues that Regulate Species SelectivityMartin A Lewis, Lisa Hunihan, John Watson, et al.
Scientific Reports|May 20, 2021
Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancersNhu-An Pham, Nikolina Radulovich, Emin Ibrahimov, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 21, 2023
Symptom screening with Targeted Early Palliative care (STEP) versus usual care for patients with advanced cancer: a mixed methods studyCamilla Zimmermann, Ashley Pope, Breffni Hannon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 17, 2022
Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer?Yifan Wang, Adeline Cuggia, Yen-I Chen, et al.
Pageof 83